Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers.
SARS-CoV-2
adverse event
healthcare workers
nocebo
tolerability
vaccine hesitancy
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
14 Oct 2021
14 Oct 2021
Historique:
received:
21
09
2021
revised:
11
10
2021
accepted:
11
10
2021
entrez:
26
10
2021
pubmed:
27
10
2021
medline:
27
10
2021
Statut:
epublish
Résumé
Among healthcare workers (HCWs), SARS-CoV-2 vaccine hesitancy may be linked to a higher susceptibility to nocebo effects, i.e., adverse events (AEs) experienced after medical treatments due to negative expectations. To investigate this hypothesis a cross-sectional survey was performed with a self-completed questionnaire that included a tool (Q-No) for the identification of nocebo-prone individuals. A total of 1309 HCWs (67.2% women; 43.4% physicians; 28.4% nurses; 11.5% administrative staff; 16.6% other personnel) completed the questionnaires, among whom 237 (18.1%) had declined vaccination. Q-No scores were ≥15 in 325 participants (24.8%) suggesting nocebo-prone behavior. In a multivariate logistic regression model with Q-No score, age, gender, and occupation as independent variables, estimated odds ratios (ORs) of vaccination were 0.43 (i.e., less likely,
Identifiants
pubmed: 34696287
pii: vaccines9101179
doi: 10.3390/vaccines9101179
pmc: PMC8541064
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Headache. 2021 Jan;61(1):157-169
pubmed: 33316102
Vaccine. 2017 Dec 14;35(49 Pt B):6872-6878
pubmed: 29128382
Vaccine. 2015 Aug 14;33(34):4180-90
pubmed: 25896377
J Headache Pain. 2017 Oct 6;18(1):102
pubmed: 28986900
Vaccine. 2015 Aug 14;33(34):4161-4
pubmed: 25896383
Semin Arthritis Rheum. 2019 Dec;49(3S):S18-S21
pubmed: 31779844
Neurol Sci. 2015 Mar;36(3):379-81
pubmed: 25249398
Vaccine. 2015 Aug 14;33(34):4165-75
pubmed: 25896384
Vaccine. 2014 May 30;32(26):3328-35
pubmed: 24291198
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Psychosom Res. 2009 Apr;66(4):323-8
pubmed: 19302890
Vaccine. 2016 Sep 22;34(41):5013-5020
pubmed: 27576074
Scand J Public Health. 2021 May 27;:14034948211018385
pubmed: 34041973
Nat Med. 2021 Aug;27(8):1385-1394
pubmed: 34272499
Nat Rev Rheumatol. 2018 Dec;14(12):727-740
pubmed: 30361674
J Headache Pain. 2020 Sep 25;21(1):117
pubmed: 32977761
Int J Clin Pharmacol Ther. 2000 Feb;38(2):47-52
pubmed: 10706190
N Engl J Med. 2021 Aug 19;385(8):678-681
pubmed: 33979506
Front Pharmacol. 2020 Feb 19;11:100
pubmed: 32140109
Lancet Reg Health Eur. 2021 Oct;9:100180
pubmed: 34308406
J Neurosci. 2008 Dec 3;28(49):13354-62
pubmed: 19052227
Vaccine. 2016 Dec 20;34(52):6700-6706
pubmed: 27810314
Vaccines (Basel). 2021 Jul 12;9(7):
pubmed: 34358193
Vaccine. 2011 Aug 26;29(37):6321-6
pubmed: 21627976
Pain. 2013 Aug;154(8):1312-7
pubmed: 23725779
Int Rev Neurobiol. 2018;139:443-462
pubmed: 30146057
PLoS One. 2020 Apr 16;15(4):e0231924
pubmed: 32298385
Mediterr J Rheumatol. 2020 Sep 21;31(Suppl 2):288-294
pubmed: 33196007
Mediterr J Rheumatol. 2019 May 31;30(Suppl 1):63-68
pubmed: 32524080
J Hosp Infect. 2021 Feb;108:168-173
pubmed: 33259883
N Engl J Med. 2020 Feb 6;382(6):554-561
pubmed: 32023375
J Pain Res. 2017 Jul 31;10:1831-1839
pubmed: 28831271
J Clin Med. 2021 Apr 01;10(7):
pubmed: 33916020
Vaccines (Basel). 2021 Feb 28;9(3):
pubmed: 33670913
Expert Rev Clin Pharmacol. 2021 Apr;14(4):439-444
pubmed: 33682603
Infect Dis Now. 2021 Aug;51(5):484-487
pubmed: 33964486